[๋ชฉ์ฐจ]

  1. Neoplasia
  2. Neuromuscular junction disorder
  3. Refractory cases

6์ฃผ์ฐจ (4/11) : N

Neoplasia

๐Ÿ“‹ Case 1 : Acquired hydrocephalus (secondary to intracranilal tumor)

O

A & P

โ‡’ Intracranial tumor์— ์˜ํ•œ aquired hydrocephalus (ํ˜ˆ๊ด€ ์‹ ์ƒ ๋ฐ ์ถœํ˜ˆ โ†’ CSF ํ๋ฆ„์ด ๋ง‰ํ˜€ hydrocephalus ๋ฐœ์ƒ) โ‡’ TDx) Choroid plexus tumor (carcinoma, papilloma) / DDx) Ependymoma โ‡’ ์กฐ์ง ๊ฒ€์‚ฌ๋ฅผ ํ†ตํ•ด ๊ฐ๋ณ„ (but ํ˜„์‹ค์ ์œผ๋กœ ๋ถ€๊ฒ€ํ•ด์•ผ ๊ฐ€๋Šฅ)

  • ์ด๋Ÿฐ ๊ฑธ paraneoplastic syndrome (์ข…์–‘์œผ๋กœ ์ธํ•ด ์ƒ๊ธฐ๋Š” ์ฆ์ƒ, ์ข…์–‘๋ถ€์ˆ˜์ฆํ›„๊ตฐ) ์ด๋ผ๊ณ  ํ•œ๋‹ค.
Treatment
PDS (1mg/kg BID)์—ผ์ฆ์„ ์ค„์—ฌ ๋‡Œ์••์„ ๋‚ฎ์ถค.
Furosemide (1mg/kg BID)์ด๋‡จ์ œ - ๋ฌผ์„ ๋ฐฐ์ถœ์‹œ์ผœ ๋‡Œ์••์„ ๋‚ฎ์ถค.
(๊ทผ๋ฐ ๋‡Œ์งˆํ™˜์—์„œ๋Š” ์ „ํ•ด์งˆ ์†์‹ค ์—†์ด ๋ฌผ๋งŒ ๋ฐฐ์ถœํ•˜๋Š” tolvaptan์ด ๋‚˜์Œ)
Omeprazole (0.7ug/kg SID)Choroid plexus์—์„œ CSF ์ƒ์„ฑ์„ ์–ต์ œ
Mannitol (1g/kg IV TID)๋‡Œ์••์„ ๋‚ฎ์ถ”๊ธฐ ์œ„ํ•ด ์‚ฌ์šฉํ•  ์ˆ˜ ์žˆ์ง€๋งŒ,
Cushing reflex, mydriasis ๋ฐœ์ƒ์„ ์ž˜ ๋ชจ๋‹ˆํ„ฐ๋ง

Neuromuscular junction disorder

  • ์‹ ๊ฒฝ์ „๋‹ฌ๋ฌผ์งˆ (acetylcholine ๋“ฑ) : nerve ending์—์„œ muscle๋กœ ์‹ ํ˜ธ ์ „๋‹ฌ, ์ ์œผ๋ฉด ๋ชธ์— ํž˜์ด ์—†์ด ๋Š˜์–ด์ง€๊ณ , ๋งŽ์œผ๋ฉด ๊ทผ์œก ๊ฐ•์ง ๋“ฑ
  • ์ค‘์ฆ๊ทผ๋ฌด๋ ฅ์ฆ โ†’ ๋›ฐ์–ด๋‹ค๋‹ˆ๋‹ค๊ฐ€ ๊ฐ‘์ž๊ธฐ ์“ฐ๋Ÿฌ์ง
    • ์„ ์ฒœ์„ฑ ์ค‘์ฆ ๊ทผ๋ฌด๋ ฅ์ฆ : acetylcholine ์ˆ˜์šฉ์ฒด๊ฐ€ ๋ถ€์กฑํ•˜๊ฒŒ ํƒœ์–ด๋‚จ.
    • Acquired myasthenia gravis (ํ›„์ฒœ์„ฑ ์ค‘์ฆ ๊ทผ๋ฌด๋ ฅ์ฆ) : acetylcholine receptor์— ๋Œ€ํ•œ antibody๊ฐ€ ํ˜•์„ฑ๋˜์–ด ๋Œ€์‹  ๋ถ™์Œ. โ†’ ๋งˆ๋น„
      • ์ง„๋‹จํ•˜๋ ค๋ฉด Ach receptor Ab๋ฅผ ๊ฒ€์‚ฌํ•˜๋ฉด ๋จ.
  • Acetylcholinesterase inhibitor (edrophonium, neostigmine, pyridostigmine) โ†’ Ach ๋ถ„ํ•ด๋ฅผ ์–ต์ œ, ์ค‘์ฆ๊ทผ๋ฌด๋ ฅ์ฆ ์น˜๋ฃŒ
    • ๋ถ€์ž‘์šฉ : ์†Œํ™”๊ธฐ๊ณ„์˜ ๊ณผ๋„ํ•œ ์šด๋™์œผ๋กœ ์„ค์‚ฌ๋ฅผ ์œ ๋ฐœํ•  ์ˆ˜ ์žˆ์Œ
  • Tensilon (edrophonium) test ๋ฅผ ํ†ตํ•ด ์ค‘์ฆ๊ทผ๋ฌด๋ ฅ์ฆ์„ ํ…Œ์ŠคํŠธํ•จ. (์น˜๋ฃŒ์  ์ง„๋‹จ)
  • ๊ตญ์†Œ์  ๋˜๋Š” ์ „์‹ ์ ์œผ๋กœ ์˜ค๋Š” motility disorder.

Megaesophagus๋ฅผ ์œ ๋ฐœํ•˜๋Š” ์›์ธ

  • Myasthenia gravis
  • Esophagitis
  • Endocrine disease (๋‚ด๋ถ„๋น„ ์งˆํ™˜)
    • hypothyroidism, Addisonโ€™s disease
  • SLE, polymyopathies (๋‹ค๋ฐœ์„ฑ ๊ทผ์—ผ)
  • Idiopathic
  • Thymoma (thymus์— ์ƒ๊ธด cancer)
  • Botulism (์Œ์‹ ์ž˜๋ชป ๋จน์–ด์„œ ๋…์†Œ ๋ฐœ์ƒ)

Further examination

  • Ach receptor antibody test
  • ANA test : SLE ๊ฐ๋ณ„
  • Thyroid profile (T4, fT4, TSH, Thyroid Ab)
  • ACTH stimulation test : Cushing, Addison ๊ฐ๋ณ„

๐Ÿ“‹ Case 2 : Acquired MG

Case) 12yrs, YT, 2.7kg, Regurgitation
๊ฒฝ๋ถ€ X-ray
- ๊ฒฝ๋ถ€ esophagus๊ฐ€ ํ™•์žฅ๋˜๊ณ , ๊ณต๊ธฐ๊ฐ€ ์ฐจ ์žˆ์Œ (๊ฒ€์€์ƒ‰)
- ์ด๋ฌผ์งˆ, ์ข…์–‘ ์˜์‹ฌ ์†Œ๊ฒฌ์€ ์•ˆ ๋ณด์ž„
- ์‹๋„์˜ motility์— ๋ฌธ์ œ๊ฐ€ ์ƒ๊ธด ๊ฒƒ์œผ๋กœ ์˜์‹ฌ, ์กฐ์˜์ œ
(์ด์ œ๋Š” ๊ธฐ์ˆ ์ด ๋ฐœ์ „ํ•ด fluoroscopy ์ดฌ์˜ํ•˜๋ฉด ๋จ)
๋ฐ”๋ฅจ ์กฐ์˜์ œ X-ray
- 5๋ถ„ ๋‚ด๋กœ ์‹๋„์—์„œ ๋ฐ”๋ฅจ ์•ˆ ๋ณด์—ฌ์•ผ ์ •์ƒ.
- ์ด ํ™˜์ž๋Š” 30๋ถ„์ด ์ง€๋‚˜๋„ ์‹๋„์—์„œ ๋ฐ”๋ฅจ ๋ณด์ž„.
- ์œ„, ์žฅ์—์„œ๋Š” ์ž˜ ์ด๋™ํ•˜๊ณ  ์žˆ์Œ.
โ‡’ ์‹๋„์˜ ์šด๋™์„ฑ ์ €ํ•˜ (esophageal hypomotility)

- Neuromuscular dz๋Š” ๋ถ€์œ„๋ณ„๋กœ ๋‹ค๋ฅด๊ฒŒ ๋‚˜ํƒ€๋‚  ์ˆ˜ ์žˆ์Œ.
- ์‹๋„ ๋ฌด๊ธด์žฅ์ฆ โ†’ ์—ฐ๋™์šด๋™ ๋ถˆ๊ฐ€๋กœ ์ธํ•œ ์—ญ๋ฅ˜
*๋ฌด๊ธด์žฅ์ฆ(atony) : ๊ทผ์œก์˜ ๊ธด์žฅ์ด ๊ฐํ‡ด ๋˜๋Š” ์†Œ์‹ค๋œ ์ƒํƒœ
*์œ„ atony โ†’ ์žฅ์œผ๋กœ ๋‚ด์šฉ๋ฌผ ์ด๋™ ๋ถˆ๊ฐ€

- ์‹๋„ ์ „์ฒด ๋งˆ๋น„๊ฐ€ ์•„๋‹Œ, ์ƒ๋ถ€ ์‹๋„ ๋ถ€๊ทผ์—๋งŒ ๋ถ€๋ถ„์ ์œผ๋กœ ๋งˆ๋น„๊ฐ€ ์˜จ ์ผ€์ด์Šค.

โ‡’ ์ค‘์ฆ ๊ทผ๋ฌด๋ ฅ์ฆ ์ดˆ๊ธฐ
Neostigmine ํˆฌ์—ฌ (tensilon test)
- Ach-esterase inhibitor ์‚ฌ์šฉ
โ†’ ์‹๋„ ๊ทผ์œก์˜ ์šด๋™์„ฑ์ด ํšŒ๋ณต๋˜์–ด ์กฐ์˜์ œ ๋‚ด๋ ค๊ฐ
- AchE inhibitor๋Š” ์†Œํ™”๊ธฐ๊ณ„์˜ ๊ณผ๋„ํ•œ ์šด๋™์œผ๋กœ ์„ค์‚ฌ ์œ ๋ฐœ ์นด๊ณต

- ์‹ ๊ฒฝ๊ทผ ๋ฌธ์ œ์˜ ๋Œ€ํ‘œ์ ์ธ ์ž„์ƒ์ฆ์ƒ์€ ๊ตฌํ† 
(๐Ÿ’Š ํ•ญ๊ตฌํ† ์ œ(antiemetics) : metronidazole, ondansetron, maropitant)
- ์ง„๋‹จ ์—†์ด ๊ตฌํ† ์— ๋Œ€ํ•œ ๋Œ€์ฆ์น˜๋ฃŒ๋งŒ?
โ†’ ์‹ฌ์žฅ๊ทผ ๋ฌธ์ œ๋กœ ์ง„ํ–‰๋˜์–ด ์‹ฌ์žฅ๋งˆ๋น„๋กœ ์‚ฌ๋งํ•  ์ˆ˜ ์žˆ์Œ.
- Ach receptor Ab ์–‘์„ฑ
โ‡’ Dx : Acquired focal Myasthenia gravis
๐Ÿ’Š pyridostigmine (1mg/kg BID PO) : AchE inhibitor
๐Ÿ’Š mosapride (1.5mg/kg BID PO) : Prokinetics

๐Ÿ“‹ Case 3 : Thymoma-induced MG

S

Schnauzer / 8Y / IM / CC : Vomiting, Regurgitation, Hypersalivation (1์ฃผ ์ „

O
  • X-ray ์ดฌ์˜

  • Fluoroscopy โ†’ ์‹๋„ ์šด๋™์„ฑ ๊ฐ์†Œ / ํ•˜๋ถ€ ์‹๋„ ๊ด„์•ฝ๊ทผ ๊ธด์žฅ๋„ ๊ฐ์†Œ / ์œ„์—์„œ ์—ญ๋ฅ˜(regurgitation)

  • Serum Ach receptor Ab ์–‘์„ฑ (2.93nmol/L)

A & P

โ‡’ Acquired myasthenia gravis (focal form)

Progress note

  • 1์ฐจ ์•ฝ๋ฌผ ์น˜๋ฃŒ | mosapride (1.5mg/kg BID), standing position after feeding
  • 1์ฃผ ๋’ค | ์ž„์ƒ ์ฆ์ƒ ๊ฐœ์„ (vomiting, regurgitation, hypersalivation), but ์•ฝ์„ ๋Š์œผ๋ฉด 8์‹œ๊ฐ„ ํ›„ ์žฌ๋ฐœ
  • 2์ฐจ ์•ฝ๋ฌผ ์น˜๋ฃŒ | ๊ณ„์† ์ฆ์ƒ ์žฌ๋ฐœ, ์น˜๋ฃŒ๊ฐ€ ์•ˆ ๋˜์–ด ์•ฝ ์šฉ๋Ÿ‰ ๋Š˜๋ฆผ โ‡’ mosapride (BID โ†’ TID)
  • ๋ถ€๋ถ„์ ์œผ๋กœ ๋ฐ˜์‘, ์‹๋„์—์„œ ์ž˜ ์•ˆ ๋‚ด๋ ค๊ฐ (Partial improvement - ์‹๋„ ์šด๋™์„ฑ ๊ฐ์†Œ, ํ•˜๋ถ€ ์‹๋„ ๊ด„์•ฝ๊ทผ ๊ธด์žฅ๋„ ๊ฐ์†Œ, mildํ•œ ์—ญ๋ฅ˜
  • 10์ฃผ ๋’ค | ์ž„์ƒ ์ฆ์ƒ ์•…ํ™” (intermittent hypersalivation) : MG ์น˜๋ฃŒ๋ฅผ 10์ฃผ ํ–ˆ๋Š”๋ฐ๋„ ํฌํ•œํ•˜๊ฒŒ ์•ˆ ๋‚˜์Œ.
  • 3์ฐจ ์•ฝ๋ฌผ ์น˜๋ฃŒ | ์•ฝ๋ฌผ ์šฉ๋Ÿ‰ ์˜ฌ๋ฆผ โ‡’ mosapride (1.5 โ†’ 2.5 mg/kg TID)
    • Barium ๋„ฃ์—ˆ์„ ๋•Œ ๋‹ค์‹œ ์ „์ฒ˜๋Ÿผ ์—„์ฒญ ์ฒœ์ฒœํžˆ ๋‚ด๋ ค๊ฐ
  • 12์ฃผ ๋’ค | ์•ฝ๋ฌผ ์šฉ๋Ÿ‰์ด ๋ถ€์กฑํ–ˆ๋‚˜..? ๊ทผ๋ฐ hypersalivation, ๋นˆ๋งฅ ๋“ฑ ๋ถ€์ž‘์šฉ๋งŒ ๋ฐœ์ƒ

(์ง€๊ธˆ๊นŒ์ง€ ๊ฒ€์‚ฌ์™€ ์น˜๋ฃŒ์—๋งŒ 1500๋งŒ์› ์ผ๋Š”๋ฐ ์ง„๋‹จ์ด ์•ˆ ๋จ..) โ†’ ์ž‘์€ thymoma๊ฐ€ ์žˆ์„ ์ˆ˜ ์žˆ์œผ๋‹ˆ ๊ฒ€์‚ฌ๋ฅผ ํ•œ๋ฒˆ ๋” ํ•ด๋ณด์ž.

CT ์ดฌ์˜
- artery๋Š” ์ž‘์ง€๋งŒ ์•ˆ์— ๋นˆ ๊ณต๊ฐ„์ด ์—†์ด ํ•˜์–—๋‹ค (ํ˜ˆ์•ก ํ๋ฆ„์ด ๋น ๋ฆ„)
- vein์€ ์ข€ ๋” ํฌ๊ณ  ๊ฐ€์šด๋ฐ๊ฐ€ ๋„๋„›์ฒ˜๋Ÿผ ๋น„์–ด ์žˆ๋‹ค (ํ˜ˆ์•ก ํ๋ฆ„์ด ๋А๋ฆผ)
- ๊ทธ๋Ÿฐ๋ฐ artery๋„ vein๋„ ์•„๋‹Œ ๋ฌด์–ธ๊ฐ€๊ฐ€ ์žˆ๋‹ค - ๋˜๊ฒŒ ์ž‘์•„์„œ X-ray์—์„œ๋„ ๋‚˜์˜ค์ง€ ์•Š์Œ.
โ‡’ CT์ƒ ์ž‘์€ thymoma๊ฐ€ ๊ด€์ฐฐ๋จ.
โ‡’ ์ˆ˜์ˆ ์ ์œผ๋กœ ์ œ๊ฑฐํ–ˆ๋”๋‹ˆ ์•ฝ๋„ ํ•„์š” ์—†์ด ์ฆ์ƒ์ด ์‹น ๋‚˜์Œ.

โ‡’ ์ตœ์ข… ์ง„๋‹จ : Thymoma์— ์˜ํ•œ ์ค‘์ฆ ๊ทผ๋ฌด๋ ฅ์ฆ (์šฐ๋ฆฌ๋‚˜๋ผ ์ตœ์ดˆ์˜ ์ผ€์ด์Šค) (๊ต๊ณผ์„œ์—์„œ๋Š” thymoma = cranial mediastinum์˜ ํฐ ์ข…์–‘์ด๋ผ๊ณ  ๋‚˜์˜ด, ํ•˜์ง€๋งŒ ์ด๋ ‡๊ฒŒ ์ž‘์€ small size thymoma๋„ ์žˆ์„ ์ˆ˜ ์žˆ๋‹ค. ๊ต๊ณผ์„œ์—๋Š” ์ „ํ˜•์ ์ธ ๊ฒƒ๋งŒ ์žˆ๋‹ค~!)

MG ๋ฐœ์ƒ ๊ธฐ์ „

โœ”๏ธ ์ „์‹ ์  MG : ๋ง‰ ์šด๋™ํ•˜๋‹ค๊ฐ€ ๊ฐ‘์ž๊ธฐ ํ”ฝ ์“ฐ๋Ÿฌ์ง€๋Š” ์• ๋“ค, edrophonium ์ฃผ๋ฉด 20์ดˆ ๋งŒ์— ๋ฒŒ๋–ก ์ผ์–ด๋‚จ.
โœ”๏ธ Focal MG : ์‹๋„/์œ„/์†Œ์žฅ/๋Œ€์žฅ์—๋งŒ ๊ตญ์†Œ์ ์œผ๋กœ ์˜ค๋Š” ๊ฒฝ์šฐ, ์†Œํ™”๊ธฐ ์šด๋™์„ฑ์ด ๋–จ์–ด์ง. โ†’ ์ฆ์ƒ์€ ์†Œํ™”๊ธฐ์ง€๋งŒ ์›์ธ์€ ์‹ ๊ฒฝํ•™์ . ์ˆ˜์ˆ ์ด ์•„๋‹ˆ๋ผ ์•ฝ๋ฌผ๋กœ ์น˜๋ฃŒํ•ด์•ผ ํ•จ.

์‹ ๊ฒฝ ์ „๋‹ฌ ๊ณผ์ •
choline acetyl transferase์— ์˜ํ•ด acetyl CoA๊ฐ€ acetylcholine์œผ๋กœ ๋ฐ”๋€œ, ์ด ๊ณผ์ •์— ์ž‘์šฉํ•˜๋Š” ๋ฏธ๋„ค๋ž„์ด Ca2+.

์ฆ‰, Ca์ด ์žˆ์–ด์•ผ๋งŒ acetylcholine์ด ๋ณด์ž๊ธฐ์ฒ˜๋Ÿผ ๋‹ด๊ฒจ, post-synapse๋กœ ์ด๋™ํ•  ์ˆ˜ ์žˆ์Œ.
  • Hypocalcemia : Ach์ด release๋˜์ง€ ๋ชปํ•ด ๊ทผ์œก ์ด์™„ (์žฅ ์šด๋™ ์ €ํ•˜ ๋“ฑ)
  • Hypercalcemia : ๊ฐ•์ง์ฆ, ์‹ฌ์žฅ ์ˆ˜์ถ•๋ ฅ ์ฆ๊ฐ€(๋นˆ๋งฅ)
    โ†’ Calcium channel blocker - Ach ์ ๊ฒŒ ๋ถ„๋น„, ํƒˆ๋ถ„๊ทน ์ง€์—ฐ, ์‹ฌ์žฅ์„ ์ฒœ์ฒœํžˆ ๋›ฐ๊ฒŒ ํ•จ / ์ด์™„๊ธฐ ๋ฌธ์ œ์ธ HCM ๋“ฑ์— ์ ์šฉ (amlodipine, verapamil, diltiazem)

Medication

  • GI tract funcion ๊ฐœ์„  ์น˜๋ฃŒ
  • Anticholinesterase therapy
  • ํ›„์ฒœ์„ฑ(์ž๊ฐ€๋ฉด์—ญ์„ฑ) โ†’ Immune suppressive therapy : thymoma์— ์˜ํ•ด ํ•ญ์ฒด๊ฐ€ ํ˜•์„ฑ, ํ•ญ์ฒด๋ฅผ ์ฐจ๋‹จํ•˜๋Š” ๋ฉด์—ญ์–ต์ œ์ œ ํ•„์š” (cyclosporine, MMF, leflunomide)

7์ฃผ์ฐจ (4/18) : N

Gastrointestinal motility ๊ด€๋ จ Receptor subtypes

Neurotransmitter์˜ ๋ฌธ์ œ์— ์˜ํ•ด ์ƒ๊ธฐ๋Š” ์†Œํ™”๊ธฐ ์งˆ๋ณ‘์ด ๋งŽ์Œ.

ReceptorAgonistAntagonist
Muscarinicpyridostigmine (+)atropine (-)
Alpha 2 adrenergicclonidine (-)
Dopamine D2dopamine (-)metoclopramide (+)
domperidone (+)
Serotonin 3 (5-HTโ‚ƒ)metoclopramide (+)
ondansetron (+)
Serotonin 4 (5-HTโ‚„)cisapride (+) : nonselective
mosapride (+) : selective

(+) : excitatory effect on motility, (-) : inhibitory effect on motility

Muscarinic receptor

  • pyridostigmine : ์žฅ ์šด๋™ ์ด‰์ง„, MG์—์„œ ์‚ฌ์šฉํ•˜๋Š” AchE inhibitor

Dopamine D2 receptor

  • ์‹ญ์ด์ง€์žฅ ์ชฝ์— ๋ถ„ํฌํ•จ
  • ๋‡Œ์—์„œ ๋„ํŒŒ๋ฏผ์ด ๋„ˆ๋ฌด ๋งŽ์ด ๋ถ„๋น„๋˜๋ฉด vomiting : ์šด๋™ ๋Šฅ๋ ฅ์ด ์ด‰์ง„๋˜์–ด ๊ณผ๋„ํ•œ ์žฅ ์šด๋™
  • ๋„ํŒŒ๋ฏผ ์ฐจ๋‹จ์ œ : metoclopramide, domeperidone
    • dopamine๊ณผ metoclopramide ๋™์‹œ์— ์“ฐ๋ฉด ์†Œ์šฉ ์—†๊ฒ ์ง€~?
  • Metoclpramide๋Š” ํ•ญ๊ตฌํ† ์ œ๋กœ ๋งค์šฐ ๋งŽ์ด ์“ฐ์ž„ : ๋„ํŒŒ๋ฏผ D2 ์ˆ˜์šฉ์ฒด๋ฅผ ์ฐจ๋‹จํ•ด์„œ ๊ตฌํ† ๊ฐ€ ์ด๋ฃจ์–ด์ง€์ง€ ์•Š๊ฒŒ ํ•˜๋Š” ๊ฒƒ

Serotonin 3 (5-HTโ‚ƒ) / Serotonin 4 (5-HTโ‚„) receptor

  • Serotonin = 5-hydroxytryptamine, 5-HT
  • Serotonin 3 & 4 ์ˆ˜์šฉ์ฒด : ์œ„์žฅ๊ด€ ์ชฝ ๋ถ„ํฌ, ํŠนํžˆ 4๋Š” ์‹๋„ ์ชฝ์— ๋งŽ์ด ๋ถ„ํฌ
    • Serotonin 3 ์ฐจ๋‹จ์ œ = ํ•ญ๊ตฌํ† ์ œ : ondansetron, metoclopramide (์„ธ๋กœํ† ๋‹Œ๊ณผ ๋„ํŒŒ๋ฏผ ์ˆ˜์šฉ์ฒด ๋‘˜ ๋‹ค ์ฐจ๋‹จ)
    • Serotonin 4 ์ฐจ๋‹จ์ œ = ์‹๋„ ์šด๋™์„ฑ ์ด‰์ง„ : cisapride, mosapride

  • Brain์˜ ์ค‘์š”ํ•œ neurotransmitter, 95%๋Š” ์œ„์žฅ๊ด€ ๊ณ„ํ†ต์— ์ž‘์šฉํ•จ.
    • cell membrane์˜ activity๋ฅผ ์ค„์—ฌ์ฃผ๋Š” ํšจ๊ณผ
    • ๋‡Œ์—์„œ ์„ธ๋กœํ† ๋‹Œ ๋ถ„๋น„๊ฐ€ ์ฆ๊ฐ€ํ•˜๋ฉด ์œ„์žฅ๊ด€ ๊ณ„ํ†ต์— ๋ฌธ์ œ (์„ค์‚ฌ, ๊ตฌํ†  ๋“ฑ)
  • Serotonin์ด ๋„ˆ๋ฌด ๋งŽ์ด ๋ถ„๋น„๋˜์–ด ๋‚˜ํƒ€๋‚˜๋Š” ์ฆ์ƒ โ†’ serotonin syndrome
  • duodenum ์ชฝ์— ๋„ํŒŒ๋ฏผ ์ˆ˜์šฉ์ฒด, ์„ธ๋กœํ† ๋‹Œ3 ์ˆ˜์šฉ์ฒด๊ฐ€ ๋งŽ์•„ ๊ตฌํ† ๊ฐ€ ์ž˜ ์ƒ๊น€. โ‡’ ์—ฌ๊ธฐ๋ฅผ ์ฐจ๋‹จํ•˜์—ฌ ๊ตฌํ† ๋ฅผ ์–ต์ œ
    • maropitant [cerenia] : ๋‡Œ์˜ vomiting center์— ์ž‘์šฉ, ์ค‘์ถ”์„ฑ ๊ตฌํ† ๋ฅผ ์–ต์ œ (๋‹ค๋ฅธ ์• ๋“ค์€ ๋‹ค ๋ง์ดˆ์„ฑ)
    • apomorphine : ๋„ํŒŒ๋ฏผ ์ˆ˜์šฉ์ฒด์— ๋ถ™์–ด์„œ ๊ตฌํ†  ์œ ๋ฐœ.

Mosapride, Cisapride (Serotonin 4 receptor)

Mosapride : selective 5-HT4 receptor agonist

  • ์‹๋„์˜ ์šด๋™์„ฑ์„ ์ด‰์ง„ (Prokinetics)
  • ์œ„์žฅ๊ด€ ์šด๋™์˜ ํšจ๊ณผ์— ๋Œ€ํ•ด in vivo/vitro study ํ–ˆ๋”๋‹ˆโ‡’ mosaspride > cisapride, 0.3-3mg/kg IV ํˆฌ์—ฌํ–ˆ๋”๋‹ˆ ์‹๋„์˜ ์šด๋™์„ฑ์ด ์ƒ๋‹นํžˆ ์ด‰์ง„
  • Affinity : metocloprimide๋ณด๋‹ค 2-12๋ฐฐ ๋†’๋‹ค.
  • Lower๋ณด๋‹ค Upper GI tract์— ํ›จ์”ฌ ์นœํ™”๋„๊ฐ€ ๋†’๋‹ค, (โ‡’ lower GI tract์—๋Š” metocloprimide)
  • ๋ถ€์ž‘์šฉ : ์‚ฌ๋žŒ์—์„œ๋Š” ๋‘ํ†ต(headache) ์•Œ๋ ค์ ธ ์žˆ๋‹ค (Headache ์ฆ‰ Migraine(ํŽธ๋‘ํ†ต)์ด๋ผ๊ณ  ํ•˜์‹ฌ; ํŽธ์ธก์œผ๋กœ ๋‚˜ํƒ€๋‚˜๋Š” ๋ฐ•๋™์„ฑ ๊ตฌํ†ต)

Cisapride : nonselective serotonin receptor agonist

  • Serotonin๋ฟ ์•„๋‹ˆ๋ผ dopamine receptor, muscarinic receptor์—๋„ ๋ถ™์Œ.
  • ์ „์ฒด GI tract์— ๋ถ™๋Š”๋‹ค โ†’ ๋ถ€์ž‘์šฉ์ด ๋” ๋งŽ๋‹ค.
    • ๋นˆ๋งฅ, ์‹ฌ์‹ค ๋นˆ๋งฅ, QT ๊ฐ„๊ฒฉ ์ฆ๊ฐ€, Extrapyramidal syndrome (์ฒ™์ˆ˜์˜ ์ถ”์ฒด๊ฐ€ ์•„๋‹ˆ๋ผ ์ถ”์ฒด ์˜† ์‹ ๊ฒฝ์„ ๋”ฐ๋ผ๊ฐ€์„œ ๋น ๋ฅด๊ฒŒ ์ „๋‹ฌ๋จ, ๊ฐ•์ง์ฆ์ด ์ž˜ ๋ฐœ์ƒ)

Dopamine ๊ด€๋ จ pathway

  • ๋‡Œ์—์„œ ๋„ํŒŒ๋ฏผ์ด ๋ถ€์กฑํ•˜๋ฉด
    • ์ธ์ง€ ๊ธฐ๋Šฅ ์ €ํ•˜, ์šด๋™ ๊ธฐ๋Šฅ ์ €ํ•˜
    • ์†์„ ๋œ๋œ ๋–ค๋‹ค (ํŒŒํ‚จ์Šจ ์ดˆ๊ธฐ ์ฆ์ƒ)
  • ๋„ํŒŒ๋ฏผ์€ monoamine oxidase(MAO) ์— ๋ถ„ํ•ด๋จ
    • ๋„ํŒŒ๋ฏผ์ด ๊ณผ๋„ํ•˜๋ฉด ๊ฐ•์ง์ฆ์ด ์˜ค๋‹ˆ๊นŒ, ๋ชธ์—์„œ ์ ๋‹นํžˆ ์“ฐ๊ณ  ๋ถ„ํ•ด์‹œํ‚ด
  • L-selegiline : MAO ์–ต์ œ์ œ, ๋„ํŒŒ๋ฏผ์„ ํ•ญ์ง„์‹œ์ผœ์„œ ์ธ์ง€๊ธฐ๋Šฅ ์ด‰์ง„ (ํŒŒํ‚จ์Šจ๋ณ‘ ๋ณด์กฐ ์น˜๋ฃŒ์— ์‚ฌ์šฉ)
    • ๋„ˆ๋ฌด ๋งŽ์œผ๋ฉด ๋ถ€์ž‘์šฉ์œผ๋กœ ๋„ํŒŒ๋ฏผ์ด ๋งŽ์•„์ ธ vomiting ์œ ๋ฐœ

Refractory cases (๋‚œ์น˜์„ฑ, ํŠน๋ฐœ์„ฑ ์ผ€์ด์Šค)

๐Ÿ“‹ Case 4 : Phenobarbital-Responsive Sialadenosis

S

11y, CM

  • ํ˜ธํก๊ณค๋ž€(Dyspnea), third eyelid ๋ถ€์Œ, ๋ถˆ์•ˆํ•ด ํ•จ
  • ๊ฐ„ํ—์  ๊ตฌํ†  (intermittent vomiting)
  • ์–ผ๊ตด์ด ๋ถ“๊ณ  (facial edema)
  • ๋ชฉ ๊ฒฝ๋ จ (spasms of neck)
  • ํƒ€์•ก์„ ์ด ์ปค์ง (enlarged mandibular & sublingual salivary glands) : ์นจ ์งˆ์งˆ

โ‡’ ์†Œํ™”๊ธฐ๊ณ„๋‚˜ ํ˜ธํก๊ธฐ๊ณ„ ์ฆ์ƒ์œผ๋กœ ๋ณด์ž„.

O
  • ๋‚ด์‹œ๊ฒฝ ๊ฒ€์‚ฌ โ‡’ ํ›„๋‘ ์ชฝ์— ๊ฑฐํ’ˆ์ด ๋งค์šฐ ๋งŽ์Œ.
    • ์œ„ ์•ˆ์— ๊ฑฐํ’ˆ์ด ์ž”๋œฉ ์žˆ๊ณ , ์ข…์–‘์ด๋‚˜ ์ด๋ฌผ์€ ์—†์Œ.
    • antrum์— ๊ฑฐํ’ˆ๋งŒ, ๊ถค์–‘์ด๋‚˜ ์ข…์–‘์€ ์—†์Œ.
    • ๋Œ€๋งŒ๋ถ€ ์ฃผ๋ฆ„ ๋ถ€์œ„๊ฐ€ ๋นจ๊ฐ›๊ธฐ๋งŒ ํ•˜๊ณ  ๋‹ค๋ฅธ ์ด์ƒ์€ ์—†์Œ.
  • ํƒ€์•ก์„  cytlogy โ†’ ์„ธํฌ ์ •์ƒ, ์ข…์–‘์ด๋‚˜ ์—ผ์ฆ ์•„๋‹˜.
  • CT, Brain MRI โ†’ NRF
  • ํ‰๊ฐ• X-ray โ†’ NRF
  • ์‚ผ์•ˆ๊ฒ€ ๋ถ€์ข…, ํ˜ธํก๊ณค๋ž€, ๊ฐ„ํ—์  ๊ตฌํ† , ์นจํ˜๋ฆผ์€ ๊ณ„์†๋จ..
  • ์ผ์ฃผ์ผ ๋™์•ˆ ์†Œํ™”๊ธฐ ์•ฝ์„ ์จ๋„ ์ฆ์ƒ์ด ๊ฐœ์„ ๋˜์ง€ ์•Š์Œ.
A & P

๊ฒ€์‚ฌ๋Š” ์ž”๋œฉ ํ–ˆ๋Š”๋ฐ ์ง„๋‹จ์ด ์•ˆ ๋‚˜์˜ค๋Š” ์ƒํ™ฉ.

์ด์Šค๋ผ์—˜์˜ ํ•œ ๋…ผ๋ฌธ์— ๋˜‘๊ฐ™์€ ์ผ€์ด์Šค๊ฐ€ ์‹ค๋ฆผ, ์น˜๋ฃŒ ๋ฐฉ๋ฒ•์œผ๋กœ phenobarbital ์ €์šฉ๋Ÿ‰์œผ๋กœ ์จ ๋ณด๋Š” ๊ฒƒ์ด ์ œ์‹œ๋จ.

  • Phenobarbital sodium (1.5mg/kg PO q12h) ์ ์šฉํ•˜์ž ํ•˜๋ฃจ ๋งŒ์— ์ฆ์ƒ์ด dramaticํ•˜๊ฒŒ ์‚ฌ๋ผ์ง.

โ‡’ Idiopathic phenobarbital-responsive sialadenosis (์ „ ์„ธ๊ณ„์—์„œ 3๋ฒˆ์งธ๋กœ ๋ณด๊ณ ๋œ ์ผ€์ด์Šค)

  • limbic epilepsy๋กœ ๋ถ„๋ฅ˜.
  • limbic์—์„œ๋Š” ํ˜ธํก, ๊ณจ๊ฒฉ๊ทผ ์šด๋™, ์†Œํ™”์ž‘์šฉ, ํ˜ธํก, ๋ฐฐ๋‡จ, ๋ฐฐ๋ณ€์— ๊ด€์—ฌํ•จ.
    • ์ธ์ง€ ๊ธฐ๋Šฅ, ๊ฐ์ •, ํ–‰๋™, ๋™๊ธฐ ๋ถ€์—ฌ, ๊ธฐ์–ต, ํ›„๊ฐ ๋“ฑ ์—ฌ๋Ÿฌ ๊ธฐ๋Šฅ์„ ๋‹ด๋‹นํ•จ.
    • ์—ฌ๊ธฐ ๋ฌธ์ œ๊ฐ€ ์ƒ๊ธฐ๋ฉด ๊ตฌํ† , ๊ทผ์œก ๋–จ๋ฆผ, ์‚ผ์•ˆ๊ฒ€ ๋Œ์ถœ, ์•„๋ฌด๋ฐ๋‚˜ ๋ฐฐ๋‡จ, ํƒ€์•ก์„  ๋น„๋Œ€ & ๋ถ„๋น„ ๋งŽ์•„์ง, ๊ฑฐํ’ˆ.
  • Clinical signs
    • retching (ํ—›๊ตฌ์—ญ์งˆ, sudden)
    • gulping (๊ฟ€๊บฝ๊ฟ€๊บฝ ์‚ผํ‚ค๋Š” ํ–‰๋™)
    • salivary gland bilateral enlargement (์–‘์ธก์„ฑ ์นจ์ƒ˜ ๋น„๋Œ€)
    • gagging (์ผ์ผ๊ฑฐ๋ฆผ)
    • lip-smacking (์ž…์ˆ ์„ ํ•ฅ์Œ์Œ)
    • weight loss, hyporexia, vomitting
    • ๋งˆ์น˜ ํ˜ธํก๊ธฐ/์†Œํ™”๊ธฐ ์งˆ๋ณ‘์ฒ˜๋Ÿผ ๋‚˜ํƒ€๋‚จ
  • ๋งค์šฐ rare
  • Generalized, partial ๋ง๊ณ  ๋งค์šฐ ๋“œ๋ฌผ๊ฒŒ limbic epilepsy๋„ ์žˆ๋‹ค๋Š” ๊ฒƒ.

โ‡’ phenobarbital(ํ•ญ๊ฒฝ๋ จ์ œ) ์“ฐ๋ฉด dramaticํ•˜๊ฒŒ ๊ฐœ์„ , ํ‰์ƒ ์•ฝ ๋จน์–ด์•ผ ํ•จ.

๐Ÿ“‹ Case 5 : Thiamine deficiency encephalopathy

๊ธ‰์„ฑ์œผ๋กœ ๋‚˜ํƒ€๋‚œ ๊ณ ์–‘์ด ์‹ ๊ฒฝ ์ฆ์ƒ. (Vestibular sign : ataxia, incoordination, circling)

Domestic Short-hair, CM, 9yPersian, SF, 6y
CCAcute hindlimb paraparesis
(๋’ท๋‹ค๋ฆฌ ๋ถ€์ „ ๋งˆ๋น„)
Progressive seizure
(์ง„ํ–‰์„ฑ ๋ฐœ์ž‘)
HistoryDiet change
(์‚ถ์€ ๋ฉธ์น˜(anchovies), ์ƒˆ์šฐ / ์ตํžŒ ๊ณ ๊ธฐ)
commercial food
BloodAzotemia, muscle enzyme ์ฆ๊ฐ€Azotemia, muscle enzyme ์ฆ๊ฐ€
MentalDull
โ†’ Intracranial ๋ฌธ์ œ
Confused
โ†’ Intracranial ๋ฌธ์ œ
PostureCervical ventroflexion (๋ชฉ ์ถ• ๋Š˜์–ด์ง)
Paraparesis โ†’ Tetraparesis
Postural reaction โ†“
Cervical ventroreflexion
Paraparesis
Incoordination
Cr. nerveMenance response (-)
PLR (-)

Vertical nystagmus / Mydriasis
Menance, PLR ๊ฐ์†Œ
Mydriasis
โ‡’ Diencephaylon, midbrain์˜ ๋ฌธ์ œ
Medulla oblangata ๋ฌธ์ œ

Brain stem ๋‹ค ๋ฌธ์ œ (Intracranial)
โ‡’ ์—ญ์‹œ Intracranial ๋ฌธ์ œ
Treatment
Thiamine HCL (50mg/kg BID PO)Thiamine HCL (โ€)
1์ผ ํ›„์‹œ๋ ฅ ํšŒ๋ณต, ์ „์ • ์ด์ƒ ํšŒ๋ณต๊ฐ„์งˆ ๋ฐœ์ž‘ ์†Œ์‹ค
2์ผ ํ›„์ •์ƒ ์ž์„ธ๋ฐ˜์‘,
๋ชจ๋“  ์ž„์ƒ์ฆ์ƒ ์†Œ์‹ค,
PLR ์ •์ƒ
BAR (normal)
1์ฃผ ํ›„์ „์ • ์ด์ƒ ๊ฐœ์„  (์•ฝ๊ฐ„์˜ ํŒŒํ–‰)
3์ฃผ ํ›„์ „์ • ์ด์ƒ ๋‹ค ์‚ฌ๋ผ์ง

โ‡’ Thiamine๋งŒ ๋จน์˜€๋Š”๋ฐ ์ฆ์ƒ์ด ์™„์ „ํžˆ ์†Œ์‹ค๋จ.

์–ด๋–ป๊ฒŒ ์ง„๋‹จํ–ˆ์„๊นŒ?

[1๋ฒˆ์งธ ์ผ€์ด์Šค] ์ดˆ๋ฐ˜์— MRI ์ดฌ์˜ํ•จ.

  • ์—ผ์ฆ์ด multifocal, ๋Œ€์นญ์ ์œผ๋กœ ์—ฌ๋Ÿฌ ๊ตฐ๋ฐ.
  • โ‡’ Systemic ๋ฌธ์ œ
  • โ‡’ Nutrition์˜ ๋ฌธ์ œ๊ตฌ๋‚˜ โ†’ thiamine ๊ฒฐํ• ์˜์‹ฌ

[2๋ฒˆ์งธ ์ผ€์ด์Šค]
  • ํ•ด์™ธ ์ˆ˜์ž… ์‚ฌ๋ฃŒ - ๋ฐฉ๋ถ€์ œ๊ฐ€ ๋งŽ์Œ.
  • ๋ถ€์„ฑ๋ถ„์—์„œ ์œ„ํ—˜ ์žˆ์„ ์ˆ˜ ์žˆ์Œ.

Thiamine

  • Vitamin B1. ์ˆ˜์šฉ์„ฑ, ํƒ„์ˆ˜ํ™”๋ฌผ์˜ ๋Œ€์‚ฌ์— ์ค‘์š”ํ•œ cofactor.
  • Thiamine ๊ฒฐํ• โ‡’ ์†Œ๋‡Œ์„ฑ, ์ „์ •๊ธฐ๊ณ„์„ฑ ์ž„์ƒ์ฆ์ƒ (์ถœํ˜ˆ ๋ณ‘๋ณ€, midbrain/cerebellum/brainstem์— ๊ดด์‚ฌ)
  • sulfadioxide โ†’ thiamine ํŒŒ๊ดดํ•˜๋ฉด์„œ ์ฆ์ƒ ๊ฐœ์„ 
  • ์ตœ์†Œ ์š”๊ตฌ ์šฉ๋Ÿ‰
    • Cats : 5mg/kg of food (1.0mg/1000kcal) - ๊ณ ์–‘์ด๋Š” ๊ด€๋ จ ํšจ์†Œ๊ฐ€ ๋ถ€์กฑํ•ด์„œ ๋” ๋งŽ์ด ํ•„์š”.
    • Dogs : 1mg/kg of food (0.3mg/1000kcal)

๊ตญ๋‚ด์‚ฌ๋ฃŒ๋“  ํ•ด์™ธ์‚ฌ๋ฃŒ๋“  ์˜์–‘๋น„๊ฐ€ ์ž˜ ์ฑ„์›Œ์ง„ ์‚ฌ๋ฃŒ๋ฅผ ๋จน๋Š” ๊ฒŒ ์ค‘์š”ํ•˜๋‹ค!